Sanofi and GlaxoSmithKline are hoping to launch their latest Covid vaccine later this year after trials found it to be particularly effective against the omicron variant, promising news for the pharmaceutical giants as they push to make up lost ground and capture part of the maturing coronavirus vaccine market.
Among adults who had already been infected with Covid, the shot was 75% effective against symptomatic infection, Sanofi said, citing its trial of more than 13,000 people. The vaccine was particularly effective at protecting against omicron infections, Sanofi said, 72% when used as a primary vaccine and 93% when used in those who have already had Covid.
The results, particularly the strong protection among those who have already been infected with Covid, complement findings from the companies’ trials testing the shot as a boosterThomas Triomphe, executive vice president at Sanofi, said the findings underscore the value of the company’s beta-based booster in a world where most people have been infected with Covid at some point, adding that the companies look forward to completing their submissions to regulators to get the shot approved.
Roger Connor, president of GSK Vaccines, said he hopes the shot will be available “later this year” and believes the vaccine has the “potential to make an important contribution to public health” as the pandemic continues to evolve.The early race to develop Covid-19 vaccines was dominated by new technology and, excluding Pfizer, which partnered with Germany’s BioNTech to make its shot, did not include any of the world’s.
Ha! More $$$$ for big pharma for something that does not work!
wait the thing that came and went last fall? damn that was fast development, these guys are genius’s
SO WHY ARE THEY STILL FORCING THE OLD, INEFFECTIVE VACCINE ON EVERYONE INCLUDING CHILDREN?!?!!